N. Kaplan

发表

Guidelines for the management of hypertension.

N. Kaplan, 2000, The Canadian journal of cardiology.

Southwestern Internal Medicine Conference: Two Faces of Sympathetic Nervous Activity—Hypotension and Hypertension

N. Kaplan, Norman M. Kaplan, 1992 .

Anxiety disorders and hyperventilation.

N. Kaplan, 1992, Archives of internal medicine.

Hypertension and diabetes

N. Kaplan, 2002, Journal of Human Hypertension.

A Conversation With Drs. Kaplan and Moser About Conflicting Data, Confusing Results, and Some Recent Treatment Recommendations for the Management of Hypertension

W. Post, M. Moser, N. Kaplan, 2005, Journal of clinical hypertension.

Alcohol and hypertension

N. Kaplan, 1995, The Lancet.

ALPHA-BLOCKADE FOR HYPERTENSION

N. Kaplan, M. Feher, R. Elkeles, 1989, The Lancet.

The Appropriate Goals of Antihypertensive Therapy: Neither Too Much Nor Too Little

N. Kaplan, 1992, Annals of Internal Medicine.

The New Hypertension Guidelines: Hits and Misses

Sanjiv J. Shah, W. Cushman, S. Nesbitt, 2021 .

Can Treating the Diastolic Blood Pressure Below a Certain Value Increase Cardiovascular Risk?

N. Kaplan, 2011, Current cardiology reports.

The diastolic J curve: alive and threatening.

N. Kaplan, 2011, Hypertension.

Prehypertension: is it relevant for nephrologists?

N. Kaplan, 2009, Clinical journal of the American Society of Nephrology : CJASN.

Treating prehypertension: A review of the evidence

N. Kaplan, 2008, Current hypertension reports.

Controversies in hypertension

L. Opie, N. Kaplan, 2006, The Lancet.

What can we expect from new guidelines?

N. Kaplan, 2004, The Medical clinics of North America.

Hypochondriasis [4] (multiple letters)

A. Barsky, N. Kaplan, 2002 .

A Possible Mechanism for Hypertension Induced by Oral Contraceptives: Diminished Feedback Suppression of Renin Release

T. Saruta, N. Kaplan, G. Saade, 1970 .

A possible mechanism for hypertension induced by oral contraceptives. Diminished feedback suppression of renin release.

T. Saruta, N. Kaplan, G. Saade, 1970, Archives of internal medicine.

The treatment of hypertension in women.

N. Kaplan, 1995, Archives of internal medicine.

Traditions of Antihypertensive Therapy in Different Countries

L. Wilhelmsen, Y. Kawano, N. Kaplan, 1990 .

The Choice of Thiazide Diuretics: Why Chlorthalidone May Replace Hydrochlorothiazide

N. Kaplan, 2009, Hypertension.

The calcium channel blocker controversy.

N. Kaplan, Norman M Kaplan, 1996, Hypertension research : official journal of the Japanese Society of Hypertension.

Comparison of the effects of guanabenz and hydrochlorothiazide on plasma lipids

S. Grundy, N. Kaplan, S. Grundy, 1988, Clinical pharmacology and therapeutics.

Microalbuminuria: a risk factor for vascular and renal complications of hypertension.

N. Kaplan, 1992, The American journal of medicine.

The meaning of ALLHAT

N. Kaplan, 2003, Journal of hypertension.

The early morning rise in blood pressure is related mainly to ambulation.

N. Kaplan, A. Khoury, P. Sunderajan, 1992, American journal of hypertension.

Factor V Leiden: A Clinical Review

N. Kaplan, B. Palmer, Rayman W Lee, 2001, The American journal of the medical sciences.

J-curve not burned off by HOT study

N. Kaplan, 1998, The Lancet.

Vasopressin: New Uses in Critical Care

Peter W. Chen, N. Kaplan, B. Palmer, 2002, The American journal of the medical sciences.

Antihypertensive therapy in the elderly. Effects on blood pressure and cerebral blood flow.

M. Devous, S. C. Forland, R. Cutler, 1987, The American journal of medicine.

Meta-analysis of hypertension treatment trials

J. Cruickshank, M. Alderman, N. Kaplan, 1990, The Lancet.

Plasma renin activity in the diagnosis of primary aldosteronism: failure to distinguish primary aldosteronism from essential hypertension.

N. Kaplan, A. Jose, 1969, Archives of internal medicine.

Commentary on incidence of primary aldosteronism: current estimations based on objective data.

N. Kaplan, 1969, Archives of internal medicine.

Suppressed plasma renin activity in essential hypertension. Roles of plasma volume, blood pressure, and sympathetic nervous system.

N. Kaplan, J. Crout, A. Jose, 1970, Annals of internal medicine.

Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension.

C. Ayers, E. Halm, A. Pandey, 2014, Journal of the American College of Cardiology.

[New European guidelines for the management of arterial hypertension: an American perspective].

N. Kaplan, 2007, Polskie Archiwum Medycyny Wewnetrznej.

The current epidemic of primary aldosteronism: causes and consequences

N. Kaplan, 2004, Journal of hypertension.

The place of diuretics in preventing cardiovascular events

N. Kaplan, 2004, Journal of Human Hypertension.

Importance of coronary heart disease risk factors in the management of hypertension. An overview.

N. Kaplan, 1989, The American journal of medicine.

Therapy for mild hypertension. Toward a more balanced view.

N. Kaplan, 1983 .

A differing view of treatment of hypertension in patients with diabetes mellitus.

P. Raskin, J. Rosenstock, N. Kaplan, 1987, Archives of internal medicine.

Prevention of Coronary Heart Disease: Practical Management of the Risk Factors

J. Stamler, N. Kaplan, 1983 .

The dietary guideline for sodium: should we shake it up? No.

N. Kaplan, 2000, The American journal of clinical nutrition.

Antihypertensive therapy to maximally reduce coronary risk.

N. Kaplan, 1993, American heart journal.

Treatment of hypertension: remaining issues after the Anglo-Scandinavian Cardiac Outcomes Trial.

N. Kaplan, 2006, Hypertension.

The ASCOT trial: a closer look

N. Kaplan, 2006, Journal of hypertension.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension: are they equivalent?

N. Kaplan, 2015, Journal of the American Society of Hypertension : JASH.

New approaches to the treatment of hypertension

N. Kaplan, 1991, Cardiovascular Drugs and Therapy.

Treating hypertension to prevent coronary disease.

N. Kaplan, 1991, Cleveland Clinic journal of medicine.

Treatment of patients with mild hypertension.

N. Kaplan, D. Hyman, 1985, Hypertension.

The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators.

N. Kaplan, 1996, Clinical therapeutics.

Two dilemmas of diabetes.

N. Kaplan, 1991, Archives of internal medicine.

Primary hypertension. From pathophysiology to prevention.

N. Kaplan, 1996, Archives of internal medicine.

The editor's roundtable: concurrent hypertension and dyslipidemia.

W. Roberts, J. Pool, V. Friedewald, 2007, The American journal of cardiology.

Strategies to reduce risk factors in hypertensive patients who smoke.

N. Kaplan, 1988, American heart journal.

Hypertension induced by pregnancy, oral contraceptives, and postmenopausal replacement therapy.

N. Kaplan, 1988, Cardiology clinics.

Syndromes X: two too many.

N. Kaplan, 1992, The American journal of cardiology.

Hypertension and Diabetes

N. Kaplan, M. Tuncel, 2004 .

Management of low-renin hypertension.

N. Kaplan, 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

J. Cutler, A. Chobanian, E. Roccella, 1984, Archives of internal medicine.

Choice of initial therapy for hypertension

N. Kaplan, R. Gifford, 1996 .

Hypertension in the elderly.

N. Kaplan, 1995, Annual review of medicine.

Hypogonadism in young men (with emphasis on Klinefelter's syndrome).

N. Kaplan, R. G. Norfleet, 1961, Annals of internal medicine.

Anxiety-induced hyperventilation. A common cause of symptoms in patients with hypertension.

N. Kaplan, 1997, Archives of internal medicine.

Potassium supplementation in hypertensive patients with diuretic-induced hypokalemia.

P. Raskin, N. Kaplan, M. Simmons, 1985, The New England journal of medicine.

Vascular outcome in type 2 diabetes: an ADVANCE?

N. Kaplan, 2007, The Lancet.

Snuff-induced hypertension in pheochromocytoma.

M. Mcphaul, N. Kaplan, R. Rude, 1984, JAMA.

Expectations Fulfilled and Unfulfilled

N. Kaplan, 2007 .

Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism.

N. Kaplan, 2006, Journal of hypertension.

Hypertension: Combination therapy for hypertension

N. Kaplan, 2009, Nature Reviews Cardiology.

Clinical trials for hypertension: expectations fulfilled and unfulfilled.

N. Kaplan, 2007, Hypertension.

II. Alternating Monotherapy is the Preferred Treatment

N. Kaplan, 1985 .

Therapy for mild hypertension. Toward a more balanced view.

N. Kaplan, 1983, JAMA.

Primary aldosteronism: evidence against a second epidemic.

N. Kaplan, 2012, Journal of Hypertension.

A plea for two actions that need to be taken.

N. Kaplan, 1991, The American journal of cardiology.

Is There an Unrecognized Epidemic of Primary Aldosteronism? (Con)

N. Kaplan, 2007 .

Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy.

N. Kaplan, 1988, The New England journal of medicine.

Beta-blockers in hypertension: adding insult to injury.

N. Kaplan, 2008, Journal of the American College of Cardiology.

Non-drug treatment of hypertension.

N. Kaplan, 1981, Annals of internal medicine.

The Inconsistent Effects of Calcium Supplements upon Blood Pressure in Primary Hypertension

N. Kaplan, J. M. Casparian, C. Ram, 1987, The American journal of the medical sciences.

Regression of left ventricular hypertrophy in hypertension. Effects of prazosin therapy.

N. Kaplan, P. Kulkarni, C. Ram, 1989, The American journal of medicine.

Non-drug treatment of hypertension.

N. Kaplan, 1985, Australian and New Zealand journal of medicine.

Management of hypertension in diabetic patients

N. Kaplan, 2002 .

The Goldblatt Memorial Lecture: Part II: The Role of the Kidney in Hypertension

N. Kaplan, 1979, Hypertension.

Alpha- and beta-receptor blocking drugs in the treatment of hypertension.

N. Kaplan, C. Ram, 1979, Current problems in cardiology.

Renovascular and Renal Parenchymatous Hypertension

T. Lüscher, N. Kaplan, 1992, Springer Berlin Heidelberg.

Nonpharmacological Treatment of Hypertension in Diabetes Mellitus

N. Kaplan, H. Tjoa, Hong I Tjoa, 1991, Diabetes Care.

The deadly quartet and the insulin resistance syndrome: an historical overview.

N. Kaplan, 1996, Hypertension research : official journal of the Japanese Society of Hypertension.

Southwestern Internal Medicine Conference: Hormonal and Local Factors in Hypertension

N. Kaplan, 1991 .

Lofexidine in the Treatment of Hypertension: A Twice‐Daily versus Once‐Daily Dose Comparison with 24‐Hour Blood Pressure Monitoring

B. Garrett, N. Kaplan, 1981, Journal of clinical pharmacology.

Effects of Clonidine on 24‐Hour Hormonal Secretory Patterns, Cardiovascular Hemodynamics, and Central Nervous Function in Hypertensive Adolescents

N. Kaplan, D. Fixler, J. Chipman, 1980, Hypertension.

New approaches to the therapy of mild hypertension.

N. Kaplan, 1983, The American journal of cardiology.

Non-pharmacological treatment of hypertension

N. Kaplan, 1987, Proceedings of the Nutrition Society.

Propranolol in the treatment of hypertension.

N. Kaplan, O. Holland, O. Bryan Holland, 1976, The New England journal of medicine.

THE EFFECT OF ANGIOTENSIN II ON THE BLOOD PRESSURE IN HUMANS WITH HYPERTENSIVE DISEASE.

N. Kaplan, J. Silah, 1964, The Journal of clinical investigation.

ALLOPURINOL: CAN IT UNDO THE HARM DONE BY HIGH DIETARY FRUCTOSE?

N. Kaplan, 2016 .

Critique of recommendations from Working Group on Hypertension in Diabetes.

N. Kaplan, 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Role of selective alpha 1 blockers in the therapy of hypertension.

N. Kaplan, 1986, The American journal of medicine.

The prognostic implications of plasma renin in essential hypertension.

N. Kaplan, Norman M Kaplan, 1975, JAMA.

Renin profiles. The unfulfilled promises.

N. Kaplan, 1977, JAMA.

Renin and Hypertension

N. Kaplan, 1976, Angiology.

A new era in hypertension therapy. Protecting patients from premature cardiovascular disease.

N. Kaplan, 1992, Postgraduate medicine.

Effects of antihypertensive therapy on cardiac function.

N. Kaplan, 1988, American heart journal.

The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension.

N. Kaplan, 1989, Archives of internal medicine.

Essential Hypertensive Patient Effects of Antihypertensive Therapy on Insulin Resistance

N. Kaplan, 2005 .

Primary aldosteronism: an update on screening, diagnosis and treatment.

N. Kaplan, 2008, Journal of hypertension.

Adrenocortical steroidogenesis: studies on the mechanism of action of angiotensin and electrolytes.

T. Saruta, N. Kaplan, R. Cook, 1972, The Journal of clinical investigation.

The effect of ACTH, renin, angiotensin II, and various precursors on biosynthesis of aldosterone by adrenal slices.

N. Kaplan, F. Bartter, F. Barter, 1962, The Journal of clinical investigation.

Cost Considerations in the Drug Treatment of Hypertension

N. Kaplan, 1996, PharmacoEconomics.

Tolbutamide tolerance test in carbohydrate metabolism evaluation.

N. Kaplan, 1961, Archives of internal medicine.

Low-yield cigarettes.

N. Benowitz, N. Kaplan, N. E. Lee, 1984, The New England journal of medicine.

Thyroid as an adjuvant to amphetamine therapy of obesity. A controlled double-blind study.

N. Kaplan, A. Jose, 1970, The American journal of the medical sciences.

The biosynthesis of adrenal steroids: effects of angiotensin II, adrenocorticotropin, and potassium.

N. Kaplan, 1965, The Journal of clinical investigation.

Effects of antihypertensive therapy on insulin resistance.

N. Kaplan, 1992, HYPERTENSION.

The Benefits of Antihypertensive Therapy

N. Kaplan, 1982 .

Guidelines for the treatment of hypertension: an American view

N. Kaplan, 1995, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Maximally reducing cardiovascular risk in the treatment of hypertension.

N. Kaplan, 1988, Annals of internal medicine.

Recent Clinical Trials: The Good, the Bad, and the Misleading

N. Kaplan, 2008, Hypertension.

An editorial comment on Dr. Opie's editorial

N. Kaplan, 1992, Cardiovascular Drugs and Therapy.

Managing cardiovascular risk and left ventricular hypertrophy. New prospects in antihypertensive therapy. Introduction.

N. Kaplan, 1991, American heart journal.

Hyperkalemia and renin deficiency.

N. Kaplan, 1972, The New England journal of medicine.

Misdiagnosis of systemic hypertension and recommendations for improvement.

N. Kaplan, 1987, The American journal of cardiology.

New therapeutic strategies in hypertension

B. Brenner, J. Laragh, N. Kaplan, 1989 .

Trial of Preventing Hypertension (TROPHY): design and 2-year progress report.

N. Kaplan, 2004, Hypertension.

Bashing booze: the danger of losing the benefits of moderate alcohol consumption.

N. Kaplan, 1991, American heart journal.

Critical comments on recent literature. SCRAAPHY about MAPHY from HAPPHY.

N. Kaplan, 1988, American journal of hypertension.

Assessment of blood pressure control during once-a-day administration of antihypertensive drugs

R. Anderson, N. Kaplan, C. Ram, 1980 .

Single-voided urine metanephrine assays in screening for pheochromocytoma.

S. Sheps, N. Kaplan, O. Holland, 1977, Archives of internal medicine.

The steroid content of adrenal adenomas and measurements of aldosterone production in patients with essential hypertension and primary aldosteronism.

N. Kaplan, 1967, The Journal of clinical investigation.

Cautions over the current epidemic of primary aldosteronism

N. Kaplan, 2001, The Lancet.

Nonpharmacologic treatment of hypertension.

N. Kaplan, 1992, Current opinion in nephrology and hypertension.

Morning surge in blood pressure.

N. Kaplan, 2003, Circulation.

Cardiovascular risk reduction: the role of antihypertensive treatment.

N. Kaplan, 1991, The American journal of medicine.

Stress, the sympathetic nervous system and hypertension.

N. Kaplan, 1978, Journal of human stress.

Use of non-drug therapy in treating hypertension.

N. Kaplan, 1984, The American journal of medicine.

Mild hypertension. When and how to treat.

N. Kaplan, 1983, Archives of internal medicine.

Circadian rhythms of serum renin activity and serum corticosterone, prolactin, and aldosterone concentrations in the male rat on normal and low-sodium diets.

C. Gomez-Sanchez, N. Kaplan, D. Kem, 1976, Endocrinology.

A direct radioimmunoassay of corticosterone in rat serum.

C. Gomez-Sanchez, N. Kaplan, D. Kem, 1975, Endocrinology.

Lipid intervention trials in primary prevention: a critical review.

N. Kaplan, 1992, Clinical and experimental hypertension. Part A, Theory and practice.

Effectiveness of adrenalectomy and aldosterone antagonists for long-term treatment of primary aldosteronism.

N. Kaplan, 2013, Hypertension.

Pitfalls in the Interpretation of Pharmacoeconomic Studies

N. Kaplan, 1992, PharmacoEconomics.

The cost-effectiveness of antihypertensive drugs.

N. Kaplan, 1990, JAMA.

Antihypertensive drugs: how different classes can impact patients' coronary heart disease risk profile and quality of life.

N. Kaplan, 1987, The American journal of medicine.

Nicardipine and propranolol in the treatment of hypertension: similar antihypertensive but dissimilar hemodynamic actions.

N. Kaplan, C. Ram, D. Gonzalez, 1990, American heart journal.

Keeping Travelers Healthy

N. Kaplan, B. Palmer, P. Keiser, 1998 .

Southwestern Internal Medicine Conference. Keeping travelers healthy.

N. Kaplan, B. Palmer, P. Keiser, 1998, The American journal of the medical sciences.

Adrenocortical steroidogenesis: the effects of prostaglandins.

T. Saruta, N. Kaplan, 1972, The Journal of clinical investigation.

THE ANGIOTENSIN-INFUSION TEST. A NEW APPROACH TO THE DIFFERENTIAL DIAGNOSIS OF RENOVASCULAR HYPERTENSION.

N. Kaplan, J. Silah, 1964, The New England journal of medicine.

Dietary aspects of the treatment of hypertension.

N. Kaplan, 1986, Annual review of public health.

Potassium supplements for hypertension.

N. Kaplan, C. Ram, 1990, The New England journal of medicine.

Chlorthalidone versus hydrochlorothiazide: a tale of tortoises and a hare.

N. Kaplan, 2011, Hypertension.

Calcium and blood pressure

N. Kaplan, 1988, Cardiovascular Drugs and Therapy.

DIAGNOSING PRIMARY HYPERALDOSTERONISM

N. Kaplan, 1968 .

Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism.

N. Kaplan, 1967, Annals of internal medicine.

Do calcium antagonists cause cancer?

N. Kaplan, 1996, The Lancet.

Do calcium antagonists cause myocardial infarction?

N. Kaplan, 1996, The American journal of cardiology.

AIDS Vasculopathy

S. Flores, N. Kaplan, B. Palmer, 2000, The American journal of the medical sciences.

Response to Uncritical Acceptance of Combination Treatment of Angiotensin II Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor in Nondiabetic Renal Disease Trial Results

N. Kaplan, 2009 .

α-Blocker Therapy of Hypertension: An Unfulfilled Promise

N. Kaplan, A. Khoury, 1991 .

Déjà vu for primary aldosteronism

N. Kaplan, 2008, The Lancet.

Current diagnosis and treatment of primary aldosteronism

N. Kaplan, 2010, Expert review of cardiovascular therapy.

Lifestyle Modifications for Prevention and Treatment of Hypertension

N. Kaplan, 2004, Journal of clinical hypertension.

Nondrug treatment of hypertension …

N. Kaplan, 1982, Texas medicine.

On the assertion that a moderate restriction of sodium intake may have adverse health effects.

N. Kaplan, H. D. de Wardener, 1993, American journal of hypertension.

Task Force 5: The preparation of future medical practitioners (medical education at the undergraduate, graduate and postgraduate level).

N. Borhani, W. Strong, H. Blackburn, 1981, The American journal of cardiology.

Arterial protection: a neglected but crucial therapeutic goal.

N. Kaplan, 1990, The American journal of cardiology.

Maximizing antihypertensive management in the elderly.

N. Kaplan, 2000, Cleveland Clinic journal of medicine.

Response to More Fuel to the Debate on the "Epidemic of Primary Aldosteronism"

N. Kaplan, 2008 .

Role of renin classification for diuretic treatment of black hypertensive patients.

C. Gomez-Sanchez, N. Kaplan, C. Fairchild, 1979, Archives of internal medicine.

Combination therapy for systemic hypertension

N. Kaplan, 1995 .

Implications for cost-effectiveness. Combination therapy for systemic hypertension.

N. Kaplan, 1995, The American journal of cardiology.

A radioimmunoassay for plasma aldosterone by immunologic purification.

C. Gomez-Sanchez, N. Kaplan, D. Kem, 1973, The Journal of clinical endocrinology and metabolism.

Cardiovascular complications of oral contraceptives.

N. Kaplan, 1978, Annual review of medicine.

Primary aldosteronism: A contrarian view

N. Kaplan, 2011, Reviews in Endocrine and Metabolic Disorders.

Clinical Implications of Mycotoxins and Stachybotrys

N. Kaplan, B. Palmer, 2010 .

New perspectives in the treatment of hypertension with arterial disease.

N. Kaplan, 1985, Journal of cardiovascular pharmacology.

Caution about the overdiagnosis of primary aldosteronism.

N. Kaplan, 2001, Mayo Clinic proceedings.

Whom to treat: the dilemma of mild hypertension.

N. Kaplan, 1981, American heart journal.

Renin‐Angiotensin System Blockade: Therapeutic Implications Beyond Blood Pressure Control

N. Kaplan, 2007, Journal of clinical hypertension.

Efficacy of slow infusion of diazoxide in the treatment of severe hypertension without organ hypoperfusion.

B. Garrett, N. Kaplan, 1982, American heart journal.

Comments on Robertson's critical review

N. Kaplan, 1994, Cardiovascular Drugs and Therapy.

Another scare about antihypertensive therapy.

N. Kaplan, 2001, The American journal of cardiology.

Another scare about antihypertensive therapy

N. Kaplan, 2000, The Lancet.

Systolic hypertension in the elderly program (SHEP) and Swedish trial in old patients with hypertension (STOP). The promises and the potential problems.

N. Kaplan, 1992, American journal of hypertension.

The costs of antihypertensive therapy.

N. Kaplan, 1996, Archives of internal medicine.

The Deadly Quartet: Upper-Body Obesity, Glucose Intolerance, Hypertriglyceridemia, and Hypertension

N. Kaplan, 1989 .

Problems with the use of diuretics in the treatment of hypertension.

N. Kaplan, 1986, American journal of nephrology.

Moderate sodium restriction and various diuretics in the treatment of hypertension.

B. Garrett, N. Kaplan, C. Ram, 1981, Archives of internal medicine.

Potassium supplementation of diuretic therapy: pro and con.

J. Kassirer, J. Haalboom, N. Kaplan, 1985, The New England journal of medicine.

Renal dysfunction in essential hypertension.

N. Kaplan, 1983, The New England journal of medicine.

The 6th joint national committee report (JNC-6): new guidelines for hypertension therapy from the USA.

N. Kaplan, 1998, The Keio journal of medicine.

New choices for the initial drug therapy of hypertension.

N. Kaplan, 1983, The American journal of cardiology.

Hemophilus influenzae infection in adults; observations on the immune disturbance.

N. Kaplan, A. Braude, 1958, A.M.A. archives of internal medicine.

The Present and Future Use of β-Blockers

N. Kaplan, 1983, Drugs.

Effects of Guanabenz on Plasma Lipid Levels in Hypertensive Patients

N. Kaplan, 1984, Journal of cardiovascular pharmacology.

The potential benefits of nonpharmacological therapy.

N. Kaplan, 1990, American journal of hypertension.

Maxzide or Dyazide: a cautionary note.

N. Kaplan, 1985, Annals of internal medicine.

The intravenous furosemide test: a simple way to evaluate renin responsiveness.

C. Gomez-Sanchez, N. Kaplan, D. Kem, 1976, Annals of internal medicine.

Plasma Renin Activity Suppression: Duration After Withdrawal From ß-Adrenergic Blockade

B. Garrett, N. Kaplan, 1980 .

The difference between serum and plasma potassium.

N. Kaplan, D. Hyman, 1985, The New England journal of medicine.

Obesity in hypertension: effects on prognosis and treatment.

N. Kaplan, 1998, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Renal pressor material in various hypertensive diseases.

N. Kaplan, W. Goorno, 1965, Annals of internal medicine.

ANGIOTENSIN-INFUSION TEST

N. Kaplan, 1965 .

The clinical use of diuretics in the treatment of hypertension.

N. Kaplan, 1983, Clinical and experimental hypertension. Part A, Theory and practice.

THE EFFECT OF ACUTE ADMINISTRATION OF CHLOROTHIAZIDE UPON THE PRESSOR RESPONSIVENESS TO ANGIOTENSIN AND NOREPINEPHRINE.

N. Kaplan, F. Bashour, R. Jones, 1965, American heart journal.

Hypertension and hyperinsulinemia.

N. Kaplan, 1991, Primary care.

How bad are diuretic-induced hypokalemia and hypercholesterolemia?

N. Kaplan, 1989, Archives of internal medicine.

Ventrolateral medullary decompression in essential hypertension

N. Kaplan, 1998, The Lancet.

TREATMENT OF SEVERE HYPERTENSION

N. Kaplan, 1979, The Lancet.

The promises and perils of treating the elderly hypertensive.

N. Kaplan, Norman M. Kaplan, 1993, The American journal of the medical sciences.

Diuretics: cornerstone of antihypertensive therapy.

N. Kaplan, 1996, The American journal of cardiology.

Management of hypertensive emergencies

N. Kaplan, N. Kaplan, 1994, The Lancet.

Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents.

V. Papademetriou, M. Lefkowitz, N. Kaplan, 1993, The American journal of medicine.

Hypertension: prevalence, risks, and effect of therapy.

N. Kaplan, 1983, Annals of internal medicine.

MENTAL DEFICIENCY AND KLINEFELTER'S SYNDROME

N. Kaplan, 1961 .

Hypotension as a complication of promazine therapy.

N. Kaplan, 1959, A.M.A. archives of internal medicine.

Etiology and Management of Delirium

N. Kaplan, B. Palmer, V. Roche, 2003 .

Epidemiology and Clinical Importance of Renovascular and Renal Parenchymatous Hypertension

N. Kaplan, 1992 .

The case for low dose diuretic therapy.

N. Kaplan, 1991, American journal of hypertension.

Ponce de Leon’s Fountain: Stem Cells and the Regenerating Heart

D. Garry, N. Kaplan, B. Palmer, 2005, The American journal of the medical sciences.

The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

J. Cutler, A. Chobanian, E. Roccella, 1988, Archives of internal medicine.

The aldosterone-renin ratio and primary aldosteronism [3] (multiple letters)

V. Montori, S. Turner, M. Stowasser, 2002 .

Our appropriate concern about hypokalemia.

N. Kaplan, N M Kaplan, 1984, The American journal of medicine.

Acupuncture for hypertension: can 2500 years come to an end?

Norman M Kaplan, N. Kaplan, 2006, Hypertension.

Cardiovascular Gene Therapy: Angiogenesis and Beyond

R. Shohet, R. Bekeredjian, N. Kaplan, 2004, The American journal of the medical sciences.

Systemic hypertension: an overview of the problem.

N. Kaplan, 2005, Seminars in nephrology.

Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention

Bernard J. Gersh, Henry R. Black, Christopher M. O’Connor, 2007, Circulation.

Is there an unrecognized epidemic of primary aldosteronism? Con.

N. Kaplan, 2007, Hypertension.

Single-Voided Urine Metanephrine Assays in Screening for Pheochromocytoma

S. Sheps, C. Gomez-Sanchez, N. Kaplan, 1977 .

An oral contraceptive. A 4-year study of norethindrone.

N. Kaplan, J. Thayer, J. Weintraub, 1961, Obstetrics and gynecology.

Cancer from an Unknown Primary Site

N. Kaplan, B. Palmer, J. Dowell, 2003, The American journal of the medical sciences.

Moderate sodium restriction and various diuretics in the treatment of hypertension.

B. Garrett, N. Kaplan, C. Ram, 1981, Archives of internal medicine.

Dementia: When Is It Not Alzheimer Disease?

N. Kaplan, B. Palmer, B. Vicioso, 2002, The American journal of the medical sciences.

Candesartan vs losartan and mortality in patients with heart failure.

N. Kaplan, 2011, JAMA.

Should new drugs be used without outcome data? Implications of Allhat and Elite II.

N. Kaplan, 2001, Archives of internal medicine.

Educating physicians in the use of pharmaceuticals

N. Kaplan, 1985, Circulation.

NIH report on research challenges in nutrition and hypertension.

M. Blaustein, M. Horan, A. Simopoulos, 1985, Hypertension.

An updated meta-analysis with a few surprises.

N. Kaplan, 2005, Hypertension.

Therapy of mild hypertension: an overview.

N. Kaplan, 1984, The American journal of cardiology.

The calcium deficiency hypothesis of hypertension: a critique.

N. Kaplan, R. Meese, 1986, Annals of internal medicine.

Strategies for Treatment of Hypertension

N. Kaplan, 2003 .

Target organ complications and prognostic significance of alerting reaction: analysis from the Dallas Heart Study

A. Khera, C. Ayers, J. D. de Lemos, 2016, Journal of hypertension.

Diuretics as a Basis of Antihypertensive Therapy

N. Kaplan, 2012, Drugs.

Hypertension trials: 1990 to 2000

N. Kaplan, 2001, Current opinion in nephrology and hypertension.

What is goal blood pressure for the treatment of hypertension?

N. Kaplan, 2001, Archives of internal medicine.

How far to lower blood pressure.

N. Kaplan, 1992, New England Journal of Medicine.

Alpha-blockade: monotherapy for hypertension and benign prostatic hyperplasia.

S. Kaplan, N. Kaplan, Steven A. Kaplan, 1996, Urology.

Management of hypertensive patients with multiple cardiovascular risk factors.

N. Kaplan, 2001, American journal of hypertension.

New issues in the treatment of isolated systolic hypertension.

N. Kaplan, 2000, Circulation.

Task Force 5: systemic hypertension.

T. Pickering, S. Gidding, N. Kaplan, 2005, Journal of the American College of Cardiology.

Evidence in favor of moderate dietary sodium reduction.

N. Kaplan, N. Kaplan, 2000, American journal of hypertension.

Long‐term Effectiveness of Nonpharmacological Treatment of Hypertension

N. Kaplan, 1991, Hypertension.

Chapter 54 – Individualization of Pharmacologic Therapy

N. Kaplan, 2008 .

HYPERTENSION IN BLACKS: A DOUBLE DISADVANTAGE

N. Kaplan, 2015 .

Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension: Analysis From the Dallas Heart Study.

A. Khera, C. Ayers, J. D. de Lemos, 2015, Journal of the American College of Cardiology.

Treatment of hypertension in the elderly.

N. Kaplan, H. Tjoa, Hong I. Tjoa, 1990, JAMA.

Nonpharmacologic therapy of hypertension.

N. Kaplan, 1987, The Medical clinics of North America.

Community medicine as an academic discipline. Fact or fancy

N. Kaplan, 1972 .

Calcium entry blockers in the treatment of hypertension. Current status and future prospects.

N. Kaplan, 1989, JAMA.

Dredging the data on antihypertensive therapy.

N. Kaplan, 1991, American journal of hypertension.

Interaction of 16beta-hydroxydehydroepiandrosterone with renal mineralocorticoid receptors.

C. Gomez-Sanchez, N. Kaplan, D. Kem, 1977, The Journal of laboratory and clinical medicine.

Mineralocorticoid activity of 16beta-hydroxydehydroepiandrosterone and related steroids.

C. Gomez-Sanchez, N. Kaplan, J. Higgins, 1976, The Journal of laboratory and clinical medicine.

Urapidilof its Use in the Management of Hypertension

Y. Hirata, N. Kaplan, M. Hirschl, 1998 .

The Treatment of Hypertensive Emergencies and Urgencies

N. Kaplan, 1992, Heart disease and stroke : a journal for primary care physicians.

Two techniques to improve adherence to dietary sodium restriction in the treatment of hypertension.

N. Kaplan, M. Simmons, A. Carnegie, 1982, Archives of internal medicine.

Resistant hypertension

N. Kaplan, 2005, Journal of hypertension.

Target organ complications and cardiovascular events associated with masked hypertension and white coat hypertension: analysis from the dallas heart study

A. Khera, C. Ayers, Darren K Mcguire, 2015 .

ASSESSMENT OF PITUITARY ACTH SECRETORY CAPACITY WITH METOPIRONE: 1. INTERPRETATION.

N. Kaplan, 1963, The Journal of clinical endocrinology and metabolism.

Ethnic aspects of hypertension

N. Kaplan, 1994, The Lancet.

Individual titration of diazoxide dosage in the treatment of severe hypertension.

N. Kaplan, C. Ram, C. S. Ram, 1979, The American journal of cardiology.

Task force 4: Systemic hypertension

N. Kaplan, H. Miller, R. B. Deveraux, 1994 .

Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Guidelines Based on Current Evidence

N. Kaplan, 2001, Annals of Internal Medicine.

Treatment of coexisting diabetes and hypertension

N. Kaplan, 2001, Current cardiology reports.

Kaplan's Clinical Hypertension

Norman M. Kaplan, N. Kaplan, 2002 .

The sixth report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure

Henry R. Black, Norman M. Kaplan, H. Black, 1998 .

Guidelines for the treatment of hypertension.

H. Perry, M. Alderman, D. McCarron, 1989, American journal of hypertension.

Difficult Hypertension: Practical management and decision making

M. Kendall, N. Kaplan, R. Horton, 1995 .

Attenuation of Diuretic‐Induced Hypokalemia by Amiloride, a Potassium‐Sparing Agent

N. Kaplan, C. Ram, O. Holland, 1981, Journal of clinical pharmacology.

Ambulatory blood pressure monitoring: a question for now and the future.

B. Garrett, N. Kaplan, 1987, The Journal of Clinical Hypertension.

Large prospective study of ramipril in patients with hypertension. CARE Investigators.

N. Kaplan, W. Mulcahy, L. Sproul, 1993, Clinical Therapeutics.

Southwestern Internal Medicine Conference: difficult-to-treat hypertension.

N. Kaplan, 1995, The American journal of the medical sciences.

Endocrine mechanisms in hypertension

B. Brenner, J. Laragh, N. Kaplan, 1989 .

Do calcium antagonists cause death, gastrointestinal bleeding, and cancer?

N. Kaplan, 1996, The American journal of cardiology.

The control of hypertension: a therapeutic breakthrough.

N. Kaplan, 1980, American scientist.

Drug-related sexual dysfunction

N. Kaplan, 1983 .

Beta blockers in the treatment of hypertension

N. Kaplan, 1980 .

The place for beta-blockers in treating hypertension.

N. Kaplan, 1999, European heart journal.

Treating the individual hypertensive patient: Considerations on dose, sequential monotherapy and drug combinations by Hans R. Brunner et al

N. Kaplan, 1990 .

Predicting home-clinic blood pressure differences.

N. Kaplan, 2016, Journal of the American Society of Hypertension : JASH.

Out-of-office blood pressure measurements.

N. Kaplan, 1993, Current opinion in nephrology and hypertension.

Blood pressure measurement and monitoring.

N. Kaplan, 1992, Current opinion in nephrology and hypertension.

Treatment of Hypertension in Primary Care

N. Kaplan, 2000 .

Assessment of 24 hr blood pressure control during once a day administration of antihypertensive therapy

N. Kaplan, C. Ram, 1979 .

Hypertension with pregnancy and the pill

N. Kaplan, 1976 .

Goal Blood Pressure in Treating Hypertension—Reply

N. Kaplan, 2002 .

Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Guidelines Based on Current Evidence

N. Kaplan, 2001, Annals of Internal Medicine.

Low-dose combination therapy: the rationalization for an ACE inhibitor and a calcium channel blocker in higher risk patients.

N. Kaplan, 2001, American journal of hypertension.

Three recently published trials in hypertension

N. Kaplan, 1999, Current hypertension reports.

METHOPYRAPONE TEST IN PRIMARY HYPOTHYROIDISM.

N. Kaplan, 1965, The Journal of clinical endocrinology and metabolism.

Therapeutic implications from clinical trials for the treatment of hypertension.

N. Kaplan, 1986, The Journal of Clinical Hypertension.

Clinical aspects of hypertension

N. Kaplan, 1994 .

Amlodipine in the treatment of hypertension.

N. Kaplan, 1991, Postgraduate medical journal.

Nutritional and health benefits of beer.

M. Denke, N. Kaplan, B. Palmer, 2000, The American journal of the medical sciences.

The Statement on Home Blood Pressure Monitoring: A Mild Critique

N. Kaplan, 2008, Journal of clinical hypertension.

Thiazides and hypertension in the elderly.

N. Kaplan, R. Gifford, 1995, Hypertension.

26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 4: systemic hypertension.

N. Kaplan, H. Miller, R. B. Deveraux, 1994, Journal of the American College of Cardiology.

Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy.

N. Kaplan, 1988 .

Indapamide: Is It The Better Diuretic for Hypertension?

N. Kaplan, 2015 .

The Prognostic Implications of Plasma Renin in Essential Hypertension

N. Kaplan, 1975 .

Cardiology and Epidemiology and Prevention Council for High Blood Pressure Research and the Councils on Clinical Heart Disease: A Scientific Statement From the American Heart Association Treatment of Hypertension in the Prevention and Management of Ischemic

B. Gersh, S. Oparil, C. Cannon, 2007 .

Plasma renin activity suppression: duration after withdrawal from beta-adrenergic blockade.

B. Garrett, N. Kaplan, 1980, Archives of internal medicine.

Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension.

C. Ayers, E. Halm, A. Pandey, 2014, Journal of the American College of Cardiology.

Chlorthalidone versus hydrochlorothiazide: a tale of tortoises and a hare.

N. Kaplan, George C Roush, Theodore R Holford, 2011, Hypertension.

Individualized therapy of hypertension

N. Kaplan, C. Ram, 1996 .